Seer Proteograph automated platform for proteomic studies

Seer has released what it describes as the first and only automated platform for proteomic studies that enables sampling across the entire plasma proteome’s wide dynamic range, allowing discovery of novel protein variants with the reproducibility and speed needed for high-throughput studies. This is achieved via the company’s library of proprietary engineered nanoparticles.

Currently, most proteomic studies are focused on fundamental discovery and deciphering how biology works. For human health, the promise of proteomics is to improve care by correlating specific proteoforms with a given disease state. With less than 1% of functional protein mapping completed, proteomics has the potential to transform our understanding of human biology and disease at many levels, from individual cells to populations.

Seer’s Proteograph technology platform enables users to resolve biology at a fundamental level, from peptide differential expression to the identification of different biologically relevant proteoforms, by offering the four attributes proteomics studies need today: unbiased coverage, enabling users to discover new biology (and not just what they can capture); deep access, surveying across the dynamic range of proteins in complex samples without depleting or fractionating; an optimised, robust and rapid workflow to complete projects with minimal hands-on time; and scalable assay designs to power longitudinal studies.